CHM 0.00% 1.8¢ chimeric therapeutics limited

CLTX-CAR T is a game changer, page-11

  1. 5,481 Posts.
    lightbulb Created with Sketch. 8927
    glad you were able to point that out, and yes with M&A activity at heightened levels for CAR-T therapies, even at phase I trials... and FDA approvals with small sized (50-80 patients) phase II trials... this is IMO a very lucrative market to be in at the moment... getting a foot in the door when a field of medicine is in the midst of rapid growth and progress is something I find to be a very attractive opportunity... not without risk of course
 
watchlist Created with Sketch. Add CHM (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.